Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 123.23Cr 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 26Cr 183.41Cr 73Cr 918.88Cr 69Cr 68Cr 2.9TCr P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 100.98Cr 15Cr 14Cr 12Cr 11Cr 21Cr 1.44TCr 22Cr 150.3Cr 60Cr 753Cr 57Cr 56Cr 2.37TCr EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.91%
Yield 2024 *
-
Yield 2025 0.65%
27/08 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/04 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
27/02 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/25/16 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/25/08 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/25/28 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/25/24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/25/27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/25/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
20/25/20 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
18/25/18 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
03/25/03 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
29/24/29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 day+3.67%
1 week-0.36%
Current month-12.94%
1 month-12.94%
3 months+19.22%
6 months-21.12%
Current year-15.26%
1 week 20.2
Extreme 20.2
22.82
1 month 20.2
Extreme 20.2
27
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 22/07/2024
Director of Finance/CFO 34 27/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 22/07/2024
Director/Board Member 41 13/05/2019
Director/Board Member 53 24/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
+3.67%-0.36%-22.49%-37.50% 18Cr
+1.16%-1.13%-18.25%+9.38% 18TCr
+0.02%+4.24%-19.55%+15.88% 12TCr
-1.22%+0.70%+1.86%+32.59% 12TCr
+2.29%+17.36%-42.18%+8.22% 9.33TCr
-2.21%-2.91%-0.51%+75.12% 6.32TCr
-1.06%+1.75%+13.48%+74.12% 5.57TCr
-0.75%+3.73%+7.04%-23.26% 5.42TCr
-1.13%+0.00%-12.56%+30.09% 4.41TCr
+0.17%+5.85%-5.20%-11.43% 3.4TCr
Average +0.09%+3.52%-9.84%+17.32% 7.59TCr
Weighted average by Cap. -0.00%+3.09%-11.77%+21.97%

Financials

2024 2025
Net sales 24Cr 3.63Cr 3.24Cr 3Cr 2.72Cr 5.08Cr 344.85Cr 5.16Cr 36Cr 14Cr 180.68Cr 14Cr 13Cr 569.62Cr 18Cr 2.66Cr 2.37Cr 2.19Cr 1.99Cr 3.72Cr 252.27Cr 3.78Cr 26Cr 10Cr 132.18Cr 9.97Cr 9.76Cr 416.71Cr
Net income -1.58Cr -23.63L -21.11L -19.5L -17.67L -33.06L -22Cr -33.6L -2.35Cr -92.89L -12Cr -88.7L -86.81L -37Cr -5.04Cr -75.53L -67.44L -62.31L -56.46L -1.06Cr -72Cr -1.07Cr -7.5Cr -2.97Cr -38Cr -2.83Cr -2.77Cr -118.43Cr
Net Debt -21Cr -3.15Cr -2.82Cr -2.6Cr -2.36Cr -4.41Cr -299.3Cr -4.48Cr -31Cr -12Cr -156.81Cr -12Cr -12Cr -494.38Cr -22Cr -3.34Cr -2.98Cr -2.75Cr -2.49Cr -4.66Cr -316.6Cr -4.74Cr -33Cr -13Cr -165.88Cr -13Cr -12Cr -522.97Cr
Projected Income Statement - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
23/26/23 CN¥22.33 +3.67% 12,90,415
22/26/22 CN¥21.54 -1.33% 11,50,895
21/26/21 CN¥21.83 -1.93% 7,09,789
20/26/20 CN¥22.26 +2.49% 10,29,731
19/26/19 CN¥21.72 -3.08% 13,91,891

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 688217 Stock